Live Q&A: The Complete Response: Addressing Antidepressant Selection for Patients with Major Depressive DisorderPremiere Date: Wednesday, November 10, 2021
This activity will offer CE credit for:
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, November 10, 2022
|Michael E. Thase, MD (Moderator)
Professor of Psychiatry
Department of Psychiatry
Perelman School of Medicine at the University of Pennsylvania
Corporal Michael J. Crescenz Veterans Affairs Medical Center
|Karen Hyden, PhD, APN-BC, MSN/Ed, ACHPN
Area Vice President of Palliative Care, Amedisys, Inc.
|W. Clay Jackson, MD, DIpTh
Clinical Assistant Professor
Family Medicine and Psychiatry
University of Tennessee College of Medicine
Major depressive disorder (MDD) is a profoundly debilitating, lifelong disorder. Many patients do not achieve remission with initial first-line antidepressant therapy, which is typically comprised of selective serotonin reuptake inhibitors (SSRIs) or selective norepinephrine reuptake inhibitors (SNRIs). Subsequently, patients endure a high burden of treatment failure, though it is often unrecognized. Measurement-based care (MBC) is a proven strategy for monitoring treatment effectiveness and signaling clinicians when alternate strategies are warranted, yet MBC is not routinely implemented into practice.
This live Q&A session is your opportunity to ask questions about real-world strategies to incorporate MBC into routine practice to rapidly detect suboptimal treatment response and adjust treatment to improve patient outcomes.
At the end of this CE activity, participants should be able to:
- Incorporate MBC into primary care settings to identify suboptimal treatment responses with initial antidepressant therapy for MDD that can impede remission and functional recovery.
- Evaluate the impact of antidepressants with unique mechanisms of action (MOAs) on safety, efficacy, and tolerability relative to traditional antidepressants.
- Apply best practices for switching to antidepressant with a different MOA when initial response to SSRI/SNRI treatment results in residual symptoms, inadequate response, or intolerable side effects.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A, Inc., and Lundbeck
Physicians, Nurse Practitioners, PAs, Nurses, and Pharmacists
Specific CE Credit information is not available at this time. Please check again soon!
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Thase reports that he receives grants from Acadia Pharmaceuticals Inc.; Allergan; Assurex Health, Inc.; Axsome Therapeutics, Inc.; Biohaven Pharmaceuticals; Intra-Cellular Therapies, Inc.; Johnson & Johnson; Otsuka America Pharmaceutical, Inc.; Patient-Centered Outcomes Research Institute (PCORI); and Takeda Pharmaceuticals U.S.A, Inc. He is a consultant for Acadia Pharmaceuticals Inc.; Akili Inc.; Alkermes; Allergan; Axsome Therapeutics, Inc; Biohaven Pharmaceuticals; Bocemtium Consulting, S.L.; Boehringer Ingelheim International; CatalYm GmbH; Clexio Biosciences; Gerson Lehrman Group, Inc.; H. Lundbeck, A/S; Jazz Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; Merck & Co., Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer, Inc.; Sage Therapeutics, Inc.; Seelos Therapeutics, Inc.; Sunovion Pharmaceuticals Inc.; and Takeda Pharmaceuticals U.S.A, Inc. He receives royalties from the American Psychiatric Foundation; Guilford Publications; Herald House; Kluwer-Wolters; and W.W. Norton & Company, Inc.
Dr. Hyden has no disclosures to report.
Dr. Jackson reports he is a consultant for AbbVie Inc.; Alkermes; Otsuka America Pharmaceutical, Inc.; and Sunovion Pharmaceuticals Inc.
Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).